HBIO icon

Harvard Bioscience

0.6000 USD
+0.0340
6.01%
Updated Apr 1, 3:12 PM EDT
1 day
6.01%
5 days
0.96%
1 month
-26.83%
3 months
-70.44%
6 months
-76.38%
Year to date
-70.44%
1 year
-85.92%
5 years
-71.70%
10 years
-89.73%
 

About: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Employees: 416

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

36% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 25

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

1% more funds holding

Funds holding: 94 [Q3] → 95 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

1.1% less ownership

Funds ownership: 72.11% [Q3] → 71.01% (-1.1%) [Q4]

23% less capital invested

Capital invested by funds: $84.2M [Q3] → $65.1M (-$19.2M) [Q4]

96% less call options, than puts

Call options by funds: $2K | Put options by funds: $51K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$4.50
650%
upside
Avg. target
$4.50
650%
upside
High target
$4.50
650%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Benchmark
Bruce Jackson
34% 1-year accuracy
18 / 53 met price target
650%upside
$4.50
Speculative Buy
Maintained
24 Mar 2025

Financial journalist opinion

Based on 3 articles about HBIO published over the past 30 days

Neutral
GlobeNewsWire
2 weeks ago
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025:
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
Neutral
Seeking Alpha
2 weeks ago
Harvard Bioscience, Inc. (HBIO) Q4 2024 Earnings Call Transcript
Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2024 Results Conference Call March 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Jennifer Cote - CFO & Treasurer Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Fourth Quarter 2024 Harvard Bioscience Earnings Conference Call. At this time, all participants are in listen-only mode.
Harvard Bioscience, Inc. (HBIO) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024.
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Neutral
GlobeNewsWire
1 month ago
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
Neutral
GlobeNewsWire
2 months ago
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET.
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
Neutral
Seeking Alpha
4 months ago
Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call Transcript
Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Third Quarter 2024 Harvard Biosciences Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded.
Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
5 months ago
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
Neutral
Zacks Investment Research
5 months ago
2 Instruments Stocks to Watch From a Challenging Industry
The Zacks Instruments - Scientific industry participants like MTD and HBIO are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
2 Instruments Stocks to Watch From a Challenging Industry
Neutral
GlobeNewsWire
6 months ago
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
Charts implemented using Lightweight Charts™